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Background: The non-structural protein 3 (NS3) of bluetongue virus (BTV) is the second smaller non-structural protein
produced in host cells, playing an important role in BTV trafficking and release.
Results: In this study, we generated five BTV NS3-reactive monoclonal antibodies (mAbs), named 3D8, 2G9, 1B5, 4H8,
and 2B12. A panel of overlapping NS3-derived peptides representing the entirety of the BTV15 NS3 protein was screened
to identify linear peptide epitopes recognized by each mAb. Based on the initial screen, a series of progressively
truncated peptides were produced to identify the minimal linear peptide sequence required to maintain mAb
binding. We found that mAb 3D8 reacted with the motif 36PPRYA40, 2G9 reacted with the motif 82AEAFRDDVRLRQIK95,
1B5 reacted with the motif 205YNDAVRMSF213, 2B12 and 4H8 reacted with the motif 204SYNDAVRMSF213. Sequence
alignments demonstrated that these linear epitopes are highly conserved among all BTV serotypes, consistent with the
observation that each mAb was able to recognize cells infected with BTV1-24 serotypes tested and each identified B
cell epitope was able to be recognized by BTV-infect sheep serum.
Conclusion: This collection of mAbs along with defined linear epitopes may provide useful reagents for investigations
of NS3 protein function and the development of BTV group-specific diagnostics.
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Bluetongue disease (BT) is a hemorrhagic disease of
ruminants caused by bluetongue virus (BTV) which is
spread through the bite of midges of the genus Culicoides
[1–3]. BT is primarily found in the tropics, subtropics and
temperate zones due to the limited distribution of Culi-
coides midges and presents a threat to the development of
livestock farming [4–6]. Due to the severe impact of BT,
the Office International Des Epizooties (OIE) lists BT as a
notifiable disease.
BTV is the prototype member of the genus Orbivirus
within the Reoviridae family. The BTV genome consists of
10 double-stranded RNA segments differ in lengths that
encode seven structural proteins (VP1-VP7), and four non-
structural protein NS1, NS2, NS3/NS3a and NS4 [7]. The
BTV genome is contained in a double layer capsid. The* Correspondence: dlwu@hvri.ac.cn
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and accounts for approximately 40 % of the total protein
content. The inner capsid consists of VP3 and VP7, and
three secondary proteins including VP1, VP4 and VP6.
Antigenic differences in the VP2 account for the different
BTV serotypes, and 27 BTV serotypes are currently recog-
nized [8, 9]. The VP2 protein elicits the generation of neu-
tralizing antibodies in vivo, and is a viral hemagglutinin
[10]. BTV serotypes 1, 2, 3, 4, 12, 15, and 16 are prevalent
in China [11]. In addition, VP5 protein and VP2 protein
can act synergistically in biological function [12]. The VP7
protein is a BTV group-specific antigen which interacts
with VP3, VP2 and VP5, and plays a key role in synthesiz-
ing core particles. NS1 and NS2 are two major nonstruc-
tural proteins produced during early infection and play an
essential role in virus replication [13]. The smallest non-
structural protein, NS4, was recently found to play an im-
portant role in BTV virus-host interactions and may inhibit
host cell antiviral responses for some BTV serotypes [14].
The shortest genome segment, BTV-S10, contains two
opening reading frames (ORFs), which encodes the NS3
that has 229 amino acids and NS3a that has 216 aminole distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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at the N-terminus when compared to NS3. The BTV-S10
genome segment is highly conserved among different
BTV serotypes. The non-structural proteins NS3 and
NS3a produced by BTV are not components of the BTV
virion itself, but are produced in host cells during BTV
replication and formation [16]. NS3 first emerges from the
golgi apparatus and then transferred to membrane where
it primarily exists as glycosylated protein on the cytomem-
brane of host cells [14, 17, 18]. Some researches have
highlighted differences in expression patterns of NS3/
NS3a in insect cells as compared to mammalian cells [19].
NS3/NS3a is expressed at high levels in insect cells, but is
expressed at much lower levels in mammalian cells where
the release of BTV mainly depends on cytolysis [20–22].
Additional researches suggest that NS3 mediate BTV vir-
ion trafficking and release from infected cells in vivo and
in vitro at the final stage of BTV morphogenesis with
binding proteins in host cells [19, 23, 24]. However, there
is a great deal that remains unknown enough about the
structure and function of BTV NS3 protein. In this study,
we prepared five monoclonal antibodies (mAbs) against
the BTV15 NS3 protein and defined the linear epitopes
recognized by each mAb. We anticipate that these
reagents and results will provide a foundation for the de-
velopment of BTV group-specific diagnostic technologies
and facilitate studies in the structure and function of the
BTV NS3 protein.Fig. 1 Expression and purification of recombinant BTV15-NS3 protein.
a: SDS-PAGE analysis of recombinant MBP-NS3 protein produced in E.
coli. M, PageRulerTMPrestained Protein Ladder (Fermentas, Canada);
Lane 1, expression of MBP-only protein; lane 2, MBP-NS3 protein before
induction; lane 3, supernatant of cell lysate of recombinant MBP-NS3
protein after ultrasonication; lane 4, cell lysate pellet of recombinant
MBP-NS3 protein after ultrasonication; lane 5: purified recombinant
MBP-NS3. b: SDS-PAGE analysis of recombinant HIS-NS3 protein in E.
coli. M: PageRulerTMPrestained Protein Ladder (Fermentas, Canada); lane
1, expression of HIS-only protein; lane 2, HIS-NS3 protein before
induction; lane 3, supernatant of cell lysate of recombinant HIS-NS3
protein after ultrasonication; lane 4, cell lysate pellet of recombinant
HIS-NS3 protein after ultrasonication; lane 5, purified recombinant HIS-
NS3. c: WB analysis of recombinant MBP-NS3 protein and HIS-NS3
protein. M, PageRulerTMPrestained Protein Ladder (Fermentas, Canada);
Lane1, recombinant MBP-NS3 before purification; lane 2, purified
recombinant MBP-NS3; lane 3, recombinant HIS-NS3 before purification;
lane 4, purified recombinant HIS-NS3. Membranes were probed with
either an HRP-conjugated anti-MBP (left panel) or anti-HIS antibody
(right panel)Results
Prokaryotic expression and purification of recombinant
NS3 protein
The recombinant NS3 protein fused with maltose-
binding protein (MBP) tag (MBP-NS3) and the recom-
binant NS3 protein fused with a six-histidine tag (HIS-
NS3) were both successfully expressed in Escherichia
coli BL21 (DE3). MBP-NS3 was predominantly found
within the soluble fraction of the induced E. coli after
ultrasonication and was subsequently purified by amyl-
ose resin affinity chromatography (Fig. 1a). In contrast,
HIS-NS3 accumulated predominantly in inclusion bod-
ies and was therefore purified by excision of material at
the appropriate molecular weight from the acrylamide
gel (Fig. 1b). The two recombinant NS3 proteins were
recognized by an HRP-conjugated anti-MBP mAb
(Fig. 1c, left panel) and HRP-conjugated anti-histidine
mAb (Fig. 1c, right panel), respectively, by Western
blotting (WB).
Preparation and identification of mAbs against BTV15
NS3 protein
We immunized BALB/c mice with purified HIS-NS3 to
generate hybridoma lines secreting antibodies against theBTV15 NS3 protein. Hybridoma cell supernatants were
screened by indirect enzyme-linked immunosorbent assay
(ELISA) and selected hybridoma lines were subcloned by
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stably producing antibodies against BTV15 NS3 protein
were obtained and named 1B5, 2B12, 2G9, 3D8 and 4H8.
WB analysis revealed that mAbs produced by each hy-
bridoma line reacted with the native NS3 protein derived
from BTV15-infected baby hamster kidney-21 cells
(BHK-21 cells) as well as the recombinant NS3 protein
fused with MBP, but did not recognize uninfected BHK-
21 cell lysates or the MBP fusion tag alone (Fig. 2a). In
addition, each mAb was able to react with BHK-21 cells
infected with BTV15 by indirect immunofluorescence
assay (IFA), but did not bind appreciably to uninfected
BHK-21 cells (Fig. 2b). Furthermore, each mAb also
reacted with BHK-21 cells infected with all other BTV
serotypes tested (BTV1–14 and BTV16–24), demon-
strating that this collection of mAbs recognizes epitopes
that are conserved among the BTV serotypes tested
(Table 1). Whereas mAb 1B5, 2B12, 4H8, and 3D8 did
not recognize BHK-21 cells infected with Chuzan virus
(CV), Ibaraki virus (IBAV), or Akabane virus (AKAV),Fig. 2 Characterization of NS3-reactive mAbs. a. Each mAb was tested by W
NS3 protein in BTV15-infected BHK-21 cells, and its corresponding identifie
lysate of uninfected BHK-21 cells; lane 2, lysate of BTV15-infected BHK-21; la
(and lane 6): identified linear peptide epitopes for each mAb. mAbs used a
2B12 and 4H8 were evaluated against MBP-NS3-26; 2G9 was evaluated agains
BHK-21 cells were infected with BTV15 and used to evaluate mAb reactivity b
mAbs used are labeled at the lower left hand corner of each panelmAb 2G9 was able to additionally recognize IBAV-
infected BHK-21 cells (Table 1). We could not assess the
reaction of the mAbs with Epizootic hemorrhagic dis-
ease virus (EHDV) and African horse sickness virus
(AHSV) as these viruses are unavailable in our labora-
tory at present. Each of the mAbs consisted of an IgG1
heavy chain and kappa light chain, as determined using
the Mouse Monoclonal-Ab-ID kit.
Identification of B-cell epitopes recognized by BTV15
NS3-reactive mAbs
We next sought to define the linear epitopes within the
BTV15 NS3 protein recognized by each mAb. Peptide
scanning technology was used to prepare a group of 29
overlapping MBP-fused polypeptides (MBP-NS3-1 ~MBP-
NS3-29) representing the entirety of the BTV15 NS3 pro-
tein. MBP-NS3-1 ~MBP-NS3-29 were all successfully
expressed in E. coli (data not shown). MBP-NS3-1 ~MBP-
NS3-29 were respectively used as coating antigen in an in-
direct ELISA to identify the epitopes recognized by theB for reactivity against recombinant MBP-NS3 protein, native BTV15
d peptide epitope. M: PageRulerTMPrestained Protein Ladder; lane 1,
ne 3, MBP-only protein; lane 4, recombinant MBP-NS3 protein; lane 5
re labeled at the lower right hand corner of each panel. mAb 1B5,
t MBP-NS3-11; 3D8 was evaluated against MBP-NS3-4 and MBP-NS3-5. b.
y IFA. Uninfected BHK-21 cells served as negative control for each mAb.
Table 1 Analysis of reactivity of the five mAbs by IFA
mAbs BTV1-24 CV IBAV AKAV
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1B5 + + + + + + + + + + + + + + + + + + + + + + + + − − −
2B12 + + + + + + + + + + + + + + + + + + + + + + + + − − −
2G9 + + + + + + + + + + + + + + + + + + + + + + + + − + −
3D8 + + + + + + + + + + + + + + + + + + + + + + + + − − −
4H8 + + + + + + + + + + + + + + + + + + + + + + + + − − −
(+) indicates a positive reaction of the mAb with BHK-21 cells infected with the indicated virus; (−) indicates no reaction of the mAb with BHK-21 cells infected
with the indicated virus
BTV bluetongue virus, CV chuzan virus, IBAV ibaraki virus, AKAV akabane virus
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linear epitopes within the BTV15 NS3 protein were identi-
fied (Fig. 3a). mAb 3D8 recognized both MBP-NS3-4 and
MBP-NS3-5 polypeptides, suggesting that the core linear
epitope was represented by the NS3-derived sequence
33ISQPPRYA40(named E1) which was the overlapping NS3Fig. 3 Identification of minimal linear epitopes recognized by NS3-reactive
panel of 29 overlapping peptides derived from the BTV15 NS3 amino acid
bar graph. A BTV15 VP2-reactive antibody was used as a negative control. T
peats. b. mAbs were screened against a series of progressively truncated p
mAbs used are labeled on the top left corner of each bar graph. The name
to each bar graph. A BTV15 VP2 protein-reactive mAb was used as a negat
three experimental repeatssequence present in both peptides. mAb 2G9 recognized
MBP-NS3-11, which contained the NS3-derived sequence
81YAEAFRDDVRLRQIKR96 (named E2). mAbs 1B5, 2B12
and 4H8 all recognized MBP-NS3-26 which contained the
NS3-derived sequence 201KKQSYNDAVRMSFTEF216
(named E3). Then, we further confirmed the results by WBmAbs. a. NS3-reactive mAbs were screened by indirect ELISA against a
sequence. The mAb used is listed in the upper left hand corner of each
he error bars display the standard deviation of three experimental re-
eptides based on the results of the initial screen shown in panel a.
and the sequence of the peptides are specified in the table adjacent
ive control antibody. The error bars display the standard deviation of
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corresponding peptides as with the indirect ELISA results.
To define the minimal linear peptide epitopes required
for mAb recognition, we designed and synthesized a series
of progressively truncated polypeptides starting with the
initial peptides recognized by each mAb as described
above. Amino acids were progressively deleted from the
N- or C-terminus of the three peptide sequences (33ISQP
PRYA40, 81YAEAFRDDVRLRQIKR96 and 201KKQSYNDA
VRMSFTEF216). The panel of truncated peptides was
screened for mAb recognition by indirect ELISA. The
minimal peptide epitope recognized by mAb 3D8 was
36PPRYA40. The minimal linear epitope recognized by
2G9 was 82AEAFRDDVRLRQIK95. mAb 1B5 recognized
the minimal linear epitope 205YNDAVRMSF213, whereas
2B12 and 4H8 recognized the minimal linear epitope
204SYNDAVRMSF213 (Fig. 3b).
Reactivity of the identified B cell epitopes with BTV-positive
sheep serum
To assess the reactivity of the identified B cell epitopes
with BTV-positive sheep serum, the MBP-NS3-5, MBP-
NS3-11 and MBP-26 respectively containing ISQPPRYA,
YAEAFRDDVRLRQIKR and KKQSYNDAVRMSFTEF
were used for WB analysis. The results showed BTV-
positive sheep serum recognized the three identified B
cell epitopes (Fig. 4 panel 2–4), but not to react with
MBP-only protein (Fig. 4 panel 1). And the BTV-
negative sheep serum did not react with MBP-NS3-5,
MBP-NS3-11, MBP-26 or MBP-only protein (data not
shown). This demonstrates that the identified B cell
epitopes is targeted by sheep immune response in the
context of virus infection.
Location analysis of B cell identified epitopes in the
BTV15 NS3 protein
Based on the data from the PHYRE 2 online sever as
shown in Fig. 5a, the NS3 protein contains two trans-
membrane helices, located at amino acids 120–141 andFig. 4 BTV-infected sheep serum recognizes the MBP-fused protein
containing the amino acid sequences of identified B cell epitopes.
M, PageRulerTMPrestained Protein Ladder (Fermentas, Canada); Lane
1, the MBP-only protein; lane 2, MBP-NS3-5 containing ISQPPRYA;
lane 3, MBP-NS3-11 containing YAEAFRDDVRLRQIKR; lane 4, MBP-
NS3-26 containing KKQSYNDAVRMSFTEF164–181 (labeled as S1 and S2 in Fig. 5a). Amino acids
142-163are exposed to the external surface of the cyto-
plasmic membrane, and the N-terminal amino acids
1–119 and C-terminal amino acids 182–229 exist in the
cytoplasm. Therefore, the four epitopes recognized by
the panel of mAbs all map to a cytoplasmic location
(Fig. 5a).
Because the 3D structure of BTV NS3 protein was
unavailable in Protein Data Bank (PDB), several 3D
homology modeling about NS3 protein was obtained
from I-TASSER online sever. Then we had chosen one
of them according to high confidence that correspond-
ing with the information of secondary structure of NS3
protein as describes above. The locations of identified
epitopes were showed in the context of the deduced 3D
NS3 protein model (Fig. 5b and c).
Alignment and conversation analysis of the defined
epitopes
We next analyzed the level of conservation of the four de-
fined epitopes among different BTV serotypes and other
prototype members of the genus Orbivirus of the family
Reoviridae. NS3 protein sequences of viruses representing
BTV serotypes 1–27, CV, IBAV, EHDV and AHSV were
acquired from the UniProKB protein database. These NS3
protein sequences were aligned by using MegAlign soft-
ware. The alignment results showed three defined epi-
topes (82AEAFRDDVRLRQIK95, 204SYNDAVRMSF213
and 205YNDAVRMSF213) were completely conserved
among all 27 BTV serotypes (Fig. 6b and c). The epi-
tope 36PPRYA40 was maintained in BTV 1–24 serotypes,
whereas an R➔G substitution at position 38 was noted in
BTV 25 、BTV 26 and BTV27 (Fig. 6a). In contrast, the
four BTV NS3 epitopes were not as highly conserved in CV,
IBAV, EHDV and AHSV. The peptide epitope 36PPRYA40
showed little similarity among CV, IBAV, EHDVand AHSV.
CV, IBAV and EHDV displayed substitutions at 2 of 5 posi-
tions, and AHSV displayed substitutions at all 5 positions
within this defined epitope (Fig. 6a). With respect to the
BTV NS3 epitope 82AEAFRDDVRLRQIK95 (E2), CV and
AHSV displayed 6 amino acid substitutions, whereas IBAV
and EHDV displayed a single V➔L substitution at amino
acid position 90 (Fig. 6b). The closely related linear epi-
topes 204SYNDAVRMSF213 (recognized by mAb 2B12 and
4H8) and 205YNDAVRMSF213 (recognized by mAb 1B5)
were poorly conserved in CV and AHSV, but had higher
similarity with IBAV and EHDV (Fig. 6c).
Discussion
With the trends of global warming and the expansion of
activities of Culicoides midges, BT disease has raised glo-
bal attention with its extensively spreading. Up to date,
27 distinct BTV serotypes make diagnose and prevention
of BTV more difficult and complicated. How to make
Fig. 5 Structural analysis of the BTV15 NS3 protein and location analysis of epitopes on NS3 protein. a. Schematic diagram of the secondary structure
of the NS3 protein using PHYRE 2 online server. The transmembrane helices regions 120-141aa and 164-181aa (S1 and S2) separated the N-terminal
1-119aa and C-terminal 182-229aa. b and (c). location analysis of the identified B cell epitopes in the BTV NS3 protein using PyMol software. 3D
homology modeling was used by I-TASSER online sever. B ribbon diagram of the BTV NS3 protein; C presented the surfaces of B. the epitope
E1 (36PPRYA40), E2 (82AEAFRDDVRLRQIK95) and E3 (204SYNDAVRMSF213) in B and C was labled and especially shown by yellow, green and rose
red. And the transmembrane helices location(120-141aa and 164-181aa) were shown by red
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Fig. 6 Alignment of the four identified minimal linear peptide epitopes with corresponding sequences of BTV serotypes 1–27, CV, IBAV, EHDV and
AHSV. a Alignment of sequences corresponding to the BTV15 epitope sequence 36PPRYA40recognized by mAb 3D8; b Alignment of sequences
corresponding to the BTV15 epitope sequence 82AEAFRDDVRLRQIK95 recognized by mAb 2G9; c Alignment of sequences corresponding to
the BTV15 epitope sequence 204SYNDAVRMSF213 and 205YNPAVRMSF213 recognized by mAb 2B12, 1B5 and 4H8
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crucial. We focused on NS3 protein of BTV to develop
better group-specific diagnose and research reagents.
NS3 protein may represent a target for BTV group-
specific diagnose because NS3 protein is highly con-
served among different BTV serotypes. NS3 has been
shown to possess protein-protein interaction domain
that facilitate interactions with various proteins in in-
fected cells, including cellular proteins p11, ESCRT-I
protein Tsg101 and the BTV VP2 protein, involving intrafficking and release of BTV [17, 19, 25]. A study of
the antibody epitopes with NS3 protein would provide
the foundation for BTV group-specific diagnose and
structure study of NS3 protein, even facilitate study in
the contribution of NS3 on BTV trafficking and viron
release by interrupting protein-protein using NS3-
reactive mAbs.
In this study, we used prokaryotic recombinant protein
HIS-NS3 for the immunization of BALB/c mice and
MBP-NS3 for screening hybridoma supernatants for
Qin et al. Virology Journal  (2015) 12:86 Page 8 of 11NS3-reactive antibody production to exclude potential
false positive results. Five BTV-15 NS3-reactive mAbs
that recognized NS3 protein produced by BTV serotypes
1–24 were generated, which demonstrate that these anti-
bodies represent BTV group-specific mAbs.
We screened a panel of BTV15 NS3-derived peptides
to map mAb reactivity to initial B cell linear epitopes.
And the progressively truncated peptides were synthe-
sized to define the minimal B cell linear epitopes recog-
nized by these mAbs. In the initial screen, mAb 3D8
reacted with two NS3-derived peptides (MBP-NS3-4 and
MBP-NS3-5) that overlapped by 8 amino acids. The
binding of 3D8 to peptide MBP-NS3-5 resulted in a
higher OD492 value when compared to 3D8 binding to
MBP-NS3-4, suggesting that the overlapping sequence
was sufficient for 3D8 binding, but additional residues
present in MBP-NS3-5 enhanced binding. A peptide
lacking the C-terminal 40A residue of this core peptide
sequence displayed a strong reduction in 3D8 binding.
When residues at the N-terminus were progressively
deleted, no reduction in 3D8 binding was noted until
the residue 36P was deleted. Therefore, we demonstrated
that 36P and 40A were critical components of the linear
epitope. The initial screen for 2G9 binding identified the
linear epitope 81YAEAFRDDVRLRQIKR96 (E2). Deletion
of 81Y resulted in a slight reduction in 2G9 binding,
whereas deletion of 81YA82 completely abolished binding
demonstrating these residues are critical components of
the linear epitope. Truncation of the 95 K residue at the
C-terminus resulted in strongly reduced 2G9 reactivity.
This demonstrated that 82A and 95 K represent the crit-
ical residues for the 2G9 epitope.
The epitope 201KKQSYNDAVRMSFTEF216 (E3) was
recognized by mAbs 1B5, 4H8, and 2B12. Progressive
truncation of amino acid residues at the N- and C-
terminus demonstrated that 1B5, 4H8, and 2B12 each
retained maximal binding to the core peptide 203QSYN-
DAVRMSF213. Further truncation of 203QS205 strongly
reduced binding of 4H8 and abolished binding of 2B12,
but only slightly affected 1B5 binding. Subsequent re-
moval of the C-terminal 213 F abolished 1B5, 2B12 and
4H8 binding. These results demonstrate that while 1B5,
4H8, and 2B12 recognize a common linear epitope in
the BTV NS3 protein, there are slight differences in the
molecular requirements for binding that are revealed
through analysis of these progressively truncated peptides.
As the mAbs were derived from the mice, it is crutial
if these identified B cell epitopes recognized by mAbs
were actually recognized by the BTV-infected sheep
serum. We used MBP-fused polypeptides containing the
amino acid sequences of identified epitopes to verify the
reactivity of BTV-positive sheep serum with the MBP-
fused polypeptides. The result showed BTV-positive
sheep serum was able to recognized all of the identifiedB cell epitopes, demonstrating the practicability for the
BTV group-specific diagnostic system.
Based on previous research [23, 26, 27], we also used
the bioinformatic software PHYRE 2 online sever to
analyze NS3 secondary structure and mapped the loca-
tions of identified epitopes on 3D homology model of
NS3 protein in this study. we deduced that the NS3 pro-
tein exists as a transmembrane protein in host cells and
has two helices that span double-layer membranes. The
N- and C-terminal ends of the NS3 protein exist in the
cytoplasm. In addition, some residues are exposed to the
external surface of the cytoplasmic membrane. In this
accord, the B-cell epitopes recognized by these five
mAbs are all predicted to be located in the cytoplasm of
host cells. Because there is no NS3 crystal structure
available now, the I-TASSER online sever was used to
predict the 3D structure based on different templates of
high confidence by sending the primary sequence of
NS3. The analysis of NS3 protein structure could poten-
tially facilitate the function study of the NS3 protein.
Alignment of NS3 amino acid sequences of different
BTV subtypes and select prototype members of the
genus Orbivirus of the family Reoviridae(CV, IBAV,
EHDV and AHSV), showed that the defined antibody
epitopes are highly conserved among BTV serotypes, but
less conserved among other orbiviruses. This analysis
was consistent with the IFA results which demonstrated
that the mAbs reacted with BHK-21 cells infected with all
BTV serotypes tested (1–24), but not with CV-, IBAV-, or
AKAV-infected cells. One exception was mAb 2G9, which
was able to react with IBAV-infected BHK-21 cells in
addition to BTV-infected BHK-21 cells. We infer that this
is because the BTV epitope 82AEAFRDDVRLRQIK95-
recognized by 2G9 differs by only a valine-to-leucine sub-
stitution in the NS3 protein of IBAV.
Conclusions
In summary, we generated five BTV NS3 reactive mAbs
and defined four novel linear B-cell epitopes on the
NS3 protein of BTV15. The generation of this panel of
NS3-specific mAbs with defined linear peptide epitopes
may serve as a foundation for studies aiming to eluci-
date the role of NS3 protein-protein interactions on
virus replication and may be useful reagents for the de-
velopment of BTV group-specific diagnostic system.
Materials and methods
Cell lines and viruses
BHK-21 cells and the SP2/0 myeloma cell line were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Invitrogen) in a humidified incubator with 5 % CO2 at 37 °
C. Media for BHK-21 cells and SP2/0 myeloma cells were
respectively supplemented with 10 and 20 % heated-
inactivated fetal bovine serum (GIBCO, Invitrogen) along
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ml of penicillin). BTV serotypes 1–24 and CV, IBAV and
AKAV were maintained at the Harbin Veterinary Research
Institute and were propagated in BHK-21 cells using
standard techniques.
Prokaryotic expression of recombinant NS3 protein
The full length of the BTV15 S10 gene segment encod-
ing the NS3 protein (GenBank accession number
AGJ83560.1) was amplified from the pEASY-NS3 plas-
mid (available in our laboratory) using the following pri-
mer pair:
BTV15 NS3-EcoRI-F-1 ~ 19:5′-CCGAATTCATGCTA
TCCGGGCTGATCC-3′and
BTV15 NS3-HindIII-R-671 ~ 690:5′-GCAAGCTTTCA
GGTTAATGGCATTTCGA-3′
Primers included EcoRI and HindIII restriction sites
(shown in italics) at the 5′end to facilitate directional
cloning into the pMALTM-c4X expression vector (New
England Biolab Inc., USA) and the pET-30a (+) expression
vector (Novagen, USA). Plasmid construction was verified
by restriction enzyme digestion, PCR, and DNA sequen-
cing. Cloning into the pMALTM-c4X expression vector
placed the NS3 coding sequence downstream from the
malE gene, which encodes MBP and facilitates expression
of an MBP-BTV15 NS3 fusion protein. Similarly, cloning
into the pET-30a (+) expression vector facilitates expres-
sion of BTV15 NS3 fused with a N-terminal six-histidine
tag. The two recombinant plasmids, named pC4X-NS3-
BTV15 and pET-NS3-BTV15, were transformed to E. coli
to produce MBP-BTV15 NS3 protein and HIS-BTV15
NS3 protein, respectively. Recombinant NS3 protein was
induced by adding isopropyl-D-thiogalactopyranoside
(IPTG). For MBP-BTV15 NS3 protein expression, IPTG
was added to a final concentration of 1.0 mM and cells
were incubated overnight at 16 °C. For HIS-BTV15 NS3
expression, IPTG was added to a final concentration of
0.75 mM and cells were incubated for 6 h at 37 °C.
Production of recombinant NS3 protein was evaluated by
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). The HIS-NS3 protein was purified by
excision of the protein-containing band from the acryl-
amide gel. MBP-NS3 protein was purified by affinity chro-
matography using an amylose resin according to the
instructions of the pMALTMProtein Fusion and Purifica-
tion System, Version 5.01 (NEW England Biolabs Inc.,
USA). Production of the two purified recombinant BTV15
NS3 proteins was confirmed by WB as follows. Recombin-
ant proteins were boiled 5–10 min, separated by SDS-
PAGE, and transferred to nitrocellulose membranes. The
membranes were blocked with 5 % skim milk overnight at
4 °C to reduce non-specific binding. To detect MBP-
BTV15 NS3 and HIS-BTV15 NS3, a 1:4000 dilution of an
HRP-conjugated anti-MBP mAb (New England Biolab Inc.,USA) or an HRP-conjugated anti-HIS mAb (New England
Biolab Inc., USA) was added to each respective membrane.
Membranes were incubated at room temperature for 1 h
and visualized following the addition of 3,3′-diaminobenzi-
dine tetrahydrochloride (DAB; ZSGB-BIO, China) [28].
Reactions were stopped by washing with deionized water
before being photographed.Preparation and identification of mAbs against BTV15
NS3 protein
Firstly, we crushed down the gel contained the purified
HIS-BTV15-NS3 protein and acutely stirred till it pre-
sented mushy state. Then, six-week-old female BALB/c
mice were immunized subcutaneously with 100 μg HIS-
BTV15 NS3 protein as above. After 14 days, mice received
a subcutaneous booster immunization consisting of
200 μg HIS-BTV15 NS3 protein. The mice received a final
booster immunization 3 days prior to harvesting spleno-
cytes for hybridoma generation. Splenocytes were fused
with SP2/0 myeloma cells at a ratio of 4:1 using polyethyl-
ene glycol (PEG4000, Sigma-Aldrich). The cells were
seeded into 96-well plates in HAT medium (DMEM con-
taining 20 % FBS, 100 μg/ml streptomycin,100 IU/ml
penicillin,100 mM hypoxanthine, 16 mM thymidine, and
400 mM aminopterin) for 6 days at which time the media
was replaced with HT medium (HAT medium as above
lacking aminopterin) [29]. Hybridoma lines producing
NS3-reactive antibodies were sub-cloned at least 3 times
by limiting dilution. Hybridoma supernatants were
screened by indirect ELISA, WB and IFA as previously
described [29, 30].
Briefly, for ELISA, 96 well plates were sensitized at 4 °C
overnight with purified MBP-NS3 as coating antigen at
100 ng/ml. After blocked with 5 % skim milk at 37 °C for
2 h, the plates were incubated with hybridoma superna-
tants at 37 °C for 1 h, then with an HRP-conjugated goat
anti-mouse secondary antibodies at a 1:4000 dilution at
37 °C for 1 h. Finally, the substrate solution containing
ophenylenediamine (OPD) was used as color development
to evaluate the antigen-antibody reaction result.
In WB, the hybridoma supernatants were used as pri-
mary antibodies and an HRP-conjugated goat antibody
was used as secondary antibody.
For IFA, the 96 well microtiter plates were respectively
added with BTV1-24, CV, IBAV and AKAV. About
24–48 h later, BHK-21 cells were fixed with 90 % (V/V)
ethylalcohol in precooled distilled water at 4 °C for
30 min. The cells were washed with phosphate buffered
saline (PBS, pH7.4) with 0.1 % Tween-20 (Sigma, USA)
and were added in hybridoma supernatants for incubat-
ing at 37 °C for 1 h. The plates were washed again and a
FITC-conjugated goat anti-mouse IgG (Sigma, USA) was
added as secondary antibody. Finally, the plates were
Qin et al. Virology Journal  (2015) 12:86 Page 10 of 11viewed by a fluorescence microscope after three times of
additional washes.
NS3-reactive mAbs subtypes were determined using
the Mouse Monoclonal-Ab-ID kit (SBA Clonotyping
System-HRP, SouthernBiotech) as the manufacturer’s
instructions.
Expression of BTV15 NS3-derived polypeptides
In order to map the epitopes of NS3-reactive mAbs, we de-
signed and produced a panel of 29 overlapping polypep-
tides named MBP-NS3-1 ~MBP-NS3-29 covering the
entirety of the BTV15 NS3 protein. Each polypeptide of
MBP-NS3-1 ~MBP-NS3-28 in the series was 16 amino
acids in length and overlapped with adjacent peptides by 8
amino acids, for example, the first peptide corresponded to
NS3 amino acids 1–16 and the second peptide corre-
sponded to NS3 amino acids 9–24. But the last one of
MBP-NS3-29 was 5 amino acids that overlapped with
MBP-NS3-28 in order to ensure that potential linear
epitopes were represented in the NS3 peptide series. To
generate the peptide series, we synthesized 29 pairs of
complementary oligonucleotides encoding each peptide se-
quence (Additional file 1: Table S1). Oligonucleotides also
incorporated a TGA termination codon and EcoRI and
HindIII restriction sites to facilitate cloning into the
pMALTM-c4X expression plasmid, which places the pep-
tide sequence in-frame with a MBP coding sequence. Each
peptide-encoding plasmid was transformed into E. coli
BL21 (DE3) (Novagen, USA) for expression. Production of
each MBP-fused recombinant polypeptide was confirmed
by SDS-PAGE.
Epitope identification
To identify linear epitopes recognized by each mAb, the
mAbs produced as described above were initially screened
against the MBP-fused recombinant polypeptide series by
indirect ELISA and confirmed via WB. MBP-fused NS3
peptides and an MBP-only protein control were coated as
target antigen in 96 well plates. mAbs were added as the
primary antibody, and an HRP-conjugated goat anti-
mouse IgG (ZSGB-BIO, China) was used as the secondary
antibody. Absorbance readings were taken following
addition of a substrate solution containing OPD. Based on
the results of this initial screen used to identify a linear re-
gion of NS3 recognized by each mAb, we designed and
synthesized a series of progressively truncated polypep-
tides to perform a more refined mapping of the minimal
linear peptide epitope recognized by each mAb using the
approaches described above.
Detection of the reactivity of the epitopes with BTV-positive
sheep serum
To investigate whether the epitopes could be detected by
BTV-positive sheep serum, the MBP-fused polypeptidescontaining PPRYA, AEAFRDDVRLRQIK, SYNDAVRMSF
(MBP-NS3-5, MBP-NS3-11 and MBP-NS3-26 were used
here) were used to react with BTV-positive sheep serum
by WB. The WB procedure was the same as described
above. BTV-positive sheep serum available in our labora-
tory was performed as the primary antibody and HRP-
conjugated rabbit anti-sheep was the secondary antibody
(LICOR Biosciences). A BTV-negative sheep serum avail-
able in our laboratory was also been tested as a control
with the same processes.
Location analysis of identified epitopes in the BTV15 NS3
protein
We used the bioinformatic software PHYRE 2 online sever
to analyze NS3 secondary structure [31]. In order to locate
and explain the general spatial relationship of epitopes on
NS3 protein according to the homology modeling from
PDB, a 3D model of NS3 protein was generated by using
I-TASSER online sever [32, 33]. And the PyMol software
was used based on the results of I-TASSER online sever to
analyze the epitopes locations onto NS3 3D model.
Homology analysis of defined epitopes
We assessed the level of conservation of each identified
BTV15 NS3 linear epitope among representative viruses
of BTV serotypes 1–27 as well as prototype members of
the genus Orbivirus in the family Reoviridae, including
CV, IBAV, EHDV and AHSV. For each virus, we identified
the amino acid sequence corresponding to the identified
BTV15 NS3 epitope using UniProKB protein database
(http://www.uniprot.org/) and aligned the sequences for
comparison using the analytical software MegAlign
(Lasergene, DNASTAR Inc., Madison, WI, USA).
Statistical analysis
The software GraphPad Prism 5 was used for statistical
evaluation.
Additional file
Additional file 1: Table S1. Designation of 29 pairs of complementary
oligonucleotides.
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